Premiere Oncology

Santa Monica, California 90404-2111

0 studies enrolling now · 26 studies all time

What they study most

Advanced Cancer, Advanced Solid Tumors, Breast Cancer, Cancer, Colorectal Neoplasms, Gastric Cancer, Gastrointestinal Stromal Tumors, Malignant Disease, Metastastic Breast Cancer, Metastatic Pancreatic Adenocarcinoma, Metastatic Solid Tumors, Refractory/Relapsed Hematologic Malignancies, Neoplasm Metastasis

Studies at this site

• A Safety and Efficacy Study in Patients With Gastric Cancer — Completed
• Evaluating Patients With Varying Degrees of Renal Function — Completed
• Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors — Completed
• RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma — Completed
• A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer — Stopped early
• Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation With Capsule C Formulation as a Reference in Subjects With Advanced Solid Tumors — Completed
• A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function — Completed
• A Study of ARQ 171 in Patients With Advanced Solid Tumors — Stopped early
• Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer — Completed
• Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors — Completed
• Clinical Trial of Gemcitabine and Oxaliplatin in Recurrent or Metastatic Breast Cancer — Stopped early
• ABI-007 and Bevacizumab in Treating Women With Recurrent or Metastatic Breast Cancer — Status unconfirmed
• Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors — Completed
• A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer — Completed
• A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors — Completed
• Study of E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid Tumors — Completed
• Safety Study of ASONEP (Sonepcizumab/LT1009) to Treat Advanced Solid Tumors — Completed
• Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies — Completed
• Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer — Completed
• Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies — Completed
• Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS) — Completed
• Cardiac Safety Assessment Study of Picoplatin in Solid Tumors — Status unconfirmed
• ARQ 197 in Subjects With Metastatic Solid Tumors — Completed
• Safety and Efficacy Study of ARQ 501 in Adult Patients With Leiomyosarcoma — Completed
• MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors — Completed
• Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymph Node Positive Breast Cancer: A Pilot Study — Status unconfirmed